v3.22.2.2
Earnings (Loss) Per Common Share (Tables)
12 Months Ended
Jun. 30, 2022
Earnings (Loss) Per Common Share [Abstract]  
Schedule of Earnings (loss) Per Share, Basic and Diluted

Year Ended

June 30, 

2022

    

2021

Basic and diluted numerator:

Net loss attributable to iBio, Inc.

$

(50,303)

    

$

(23,207)

Preferred stock dividends – iBio CMO Preferred Tracking Stock

 

(88)

 

(260)

Net loss available to iBio, Inc. stockholders

$

(50,391)

$

(23,467)

 

 

Basic and diluted denominator:

 

 

 

 

Weighted-average common shares outstanding

 

8,721

 

7,825

 

 

Per share amount

$

(5.78)

$

(3.00)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

In Fiscal Years 2022 and 2021, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of June 30, 2022 and 2021, shares issuable which could potentially dilute future earnings included were as follows:

June 30, 

    

2022

    

2021

(in thousands)

Stock options

 

622

 

342

Warrant issued under the Transaction

    

51

    

Restricted stock units

 

21

 

27

Series 2022 Preferred

*

Shares excluded from the calculation of diluted loss per share

 

694

 

369

* Less than 1,000